Key result
In Japanese patients with venous thromboembolism, edoxaban treatment for 3 months in a real-world setting resulted in a 6.3% incidence of bleeding adverse events and a 0.8% incidence of VTE recurrence.
Why the study?
To investigate the safety and effectiveness of edoxaban in Japanese patients newly prescribed the drug to treat VTE and prevent VTE recurrence.
Is edoxaban safe and effective for the treatment and prevention of recurrence of venous thromboembolism in Japanese patients?
Observational (n=1,732)
Yes
Is edoxaban safe and effective for the treatment and prevention of recurrence of venous thromboembolism in Japanese patients?
In a real-world Japanese cohort, edoxaban demonstrated a favorable safety and effectiveness profile for VTE treatment over a 3-month period, even in patients requiring dose reduction.
No takes yet. Share an insight, caveat, or question.
Supports edoxaban in Japanese VTE patients; leaves open need for randomized confirmation of safety and efficacy.
Nakamura et al. (2019) conducted an observational in Venous thromboembolism (n=1,732). Edoxaban was evaluated on Incidence of bleeding adverse events. In Japanese patients with venous thromboembolism, edoxaban treatment for 3 months in a real-world setting resulted in a 6.3% incidence of bleeding adverse events and a 0.8% incidence of VTE recurrence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: